{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:47:14Z","timestamp":1790689634428,"version":"4.1.0"},"reference-count":47,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,6,1]]},"abstract":"<jats:p>Objective. To evaluate the safety of fluoroquinolones (FQ) in comparison with other antibiotics in pediatric patients.<\/jats:p>\n               <jats:p>Methods. A multicenter, observational, comparative cohort study was conducted between 1998 and 2000 in French pediatric departments. Patients who were receiving systemic FQ were included and matched to control patients who were receiving other antibiotics. Antibiotic-associated potential adverse events (PAEs) were recorded prospectively in both groups, and their rates were compared using univariate and multivariate analyses.<\/jats:p>\n               <jats:p>Results. Patients were recruited from 73 centers: 276 patients were exposed to FQ, and 249 composed the control group. Among patients who were exposed to FQ, 23% were younger than 2 years, 33% had cystic fibrosis, and PAEs occurred in 52 patients, leading to withdrawal for 11. The odds ratio for PAE in the FQ group was 3.7 (95% confidence interval: 1.9\u20137.5) and was not significantly modified after adjustment for potential confounders. Musculoskeletal PAEs also occurred more frequently in the FQ group (3.8%) than in controls (0.4%); they were recorded in 10 patients who were receiving standard FQ doses and were of moderate intensity and transient.<\/jats:p>\n               <jats:p>Conclusion. The rates of PAEs and musculoskeletal PAEs were higher for the FQ group than the control group. This observation supports the American Academy of Pediatrics statement restricting off-label FQ use in pediatric patients to second-line treatment in a limited number of situations.<\/jats:p>","DOI":"10.1542\/peds.111.6.e714","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"e714-e719","source":"Crossref","is-referenced-by-count":71,"title":["Fluoroquinolone Safety in Pediatric Patients: A Prospective, Multicenter, Comparative Cohort Study in France"],"prefix":"10.1542","volume":"111","author":[{"given":"Martin","family":"Chalumeau","sequence":"first","affiliation":[{"name":"Perinatal and Pediatric Pharmacology Unit, Universite\u0301 Rene\u0301-Descartes, Ho\u0302pital Saint-Vincent-de-Paul (AP\u2013HP), Paris, France"},{"name":"INSERM U149, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Tonnelier","sequence":"additional","affiliation":[{"name":"Perinatal and Pediatric Pharmacology Unit, Universite\u0301 Rene\u0301-Descartes, Ho\u0302pital Saint-Vincent-de-Paul (AP\u2013HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"d\u2019Athis","sequence":"additional","affiliation":[{"name":"Perinatal and Pediatric Pharmacology Unit, Universite\u0301 Rene\u0301-Descartes, Ho\u0302pital Saint-Vincent-de-Paul (AP\u2013HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tre\u0301luyer","sequence":"additional","affiliation":[{"name":"Perinatal and Pediatric Pharmacology Unit, Universite\u0301 Rene\u0301-Descartes, Ho\u0302pital Saint-Vincent-de-Paul (AP\u2013HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Gendrel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ho\u0302pital Saint-Vincent-de-Paul, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge\u0301rard","family":"Bre\u0301art","sequence":"additional","affiliation":[{"name":"INSERM U149, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge\u0301rard","family":"Pons","sequence":"additional","affiliation":[{"name":"Perinatal and Pediatric Pharmacology Unit, Universite\u0301 Rene\u0301-Descartes, Ho\u0302pital Saint-Vincent-de-Paul (AP\u2013HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Pediatric Fluoroquinolone Safety Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"2021120820240744900_R1","doi-asserted-by":"crossref","unstructured":"Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med.1991;324:384\u2013394","DOI":"10.1056\/NEJM199102073240606"},{"key":"2021120820240744900_R2","doi-asserted-by":"crossref","unstructured":"Schaad UB. Role of the new quinolones in pediatric practice. Pediatr Infect Dis J.1992;11:1043\u20131046","DOI":"10.1097\/00006454-199211120-00010"},{"key":"2021120820240744900_R3","doi-asserted-by":"crossref","unstructured":"Dagan R. Fluoroquinolones in paediatrics\u20131995. Drugs.1995;49:92\u201399","DOI":"10.2165\/00003495-199500492-00015"},{"key":"2021120820240744900_R4","doi-asserted-by":"crossref","unstructured":"Gendrel D, Moulin F. Fluoroquinolones in paediatrics. Paediatr Drugs.2001;3:365\u2013377","DOI":"10.2165\/00128072-200103050-00005"},{"key":"2021120820240744900_R5","doi-asserted-by":"crossref","unstructured":"Maggiolo F, Caprioli S, Suter F. Risk\/benefit analysis of quinolone use in children: the effect on diarthrodial joints. J Antimicrob Chemother.1990;26:469\u2013471","DOI":"10.1093\/jac\/26.4.469"},{"key":"2021120820240744900_R6","unstructured":"Schmidt M, Hoffmann K. The use of quinolones in children\u2014toxicological aspects. Adv Antimicrob Antineopl Chemother.1992;11\u20132s:251\u2013255"},{"key":"2021120820240744900_R7","doi-asserted-by":"crossref","unstructured":"Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med.1989;87:37S\u201339S","DOI":"10.1016\/0002-9343(89)90018-1"},{"key":"2021120820240744900_R8","doi-asserted-by":"crossref","unstructured":"Jawad AS. Cystic fibrosis and drug-induced arthropathy. Br J Rheumatol.1989;28:179\u2013180","DOI":"10.1093\/rheumatology\/28.2.179-a"},{"key":"2021120820240744900_R9","doi-asserted-by":"crossref","unstructured":"Alfaham M, Holt ME, Goodchild MC. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. Br Med J (Clin Res Ed).1987;295:699 (letter)","DOI":"10.1136\/bmj.295.6600.699"},{"key":"2021120820240744900_R10","unstructured":"Chaslerie A, Bannwarth B, Fillol M, Joussein M, Laborde-Laulhe AM, Begaud B. Polyarthropathy in an adolescent treated with pefloxacin. Therapie.1992;47:80 (letter)"},{"key":"2021120820240744900_R11","unstructured":"Kesseler A, Lacassie A, Hugot JP, Talon P, Thomas D, Astier L. Arthropathies following the administration of pefloxacin to an adolescent with mucoviscidosis. Ann Pediatr (Paris).1989;36:275\u2013278"},{"key":"2021120820240744900_R12","unstructured":"Seigneuric C, Plantavid M, Bouygues D, Cassou M, Amar J, Cascarigny F. Joint manifestations of pefloxacin in adolescents. Presse Med.1990;19:428 (letter)"},{"key":"2021120820240744900_R13","unstructured":"Touzet P, Thibaud D. Hydrarthrosis complicating a treatment with pefloxacine in a 14-year-old adolescent. Arch Fr Pediatr.1991;48:151\u2013152"},{"key":"2021120820240744900_R14","doi-asserted-by":"crossref","unstructured":"Chevalier X, Albengres E, Voisin MC, Tillement JP, Larget-Piet B. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Saf.1992;7:310\u2013314","DOI":"10.2165\/00002018-199207040-00007"},{"key":"2021120820240744900_R15","doi-asserted-by":"crossref","unstructured":"Chang H, Chung MH, Kim JH. Pefloxacin-induced arthropathy in an adolescent with brain abscess. Scand J Infect Dis.1996;28:641\u2013643","DOI":"10.3109\/00365549609037977"},{"key":"2021120820240744900_R16","doi-asserted-by":"crossref","unstructured":"Schaad UB. Pediatric use of quinolones. Pediatr Infect Dis J.1999;18:469\u2013470","DOI":"10.1097\/00006454-199905000-00015"},{"key":"2021120820240744900_R17","doi-asserted-by":"crossref","unstructured":"Aradottir E, Yogev R. The use of fluoroquinolones in pediatrics\u2014a reassessment. Semin Pediatr Infect Dis.1999;10:31\u201337","DOI":"10.1016\/S1045-1870(99)80007-7"},{"key":"2021120820240744900_R18","doi-asserted-by":"crossref","unstructured":"Schaad UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J.1995;14:1\u20139","DOI":"10.1097\/00006454-199501000-00001"},{"key":"2021120820240744900_R19","unstructured":"American Academy of Pediatrics. Antimicrobial agents and related therapy. Fluoroquinolones. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:645\u2013646"},{"key":"2021120820240744900_R20","doi-asserted-by":"crossref","unstructured":"Pariente-Khayat A, Vauzelle-Kervroedan F, d\u2019Athis P, et al. Retrospective survey of fluoroquinolone use in children. Arch Pediatr.1998;5:484\u2013488","DOI":"10.1016\/S0929-693X(99)80311-X"},{"key":"2021120820240744900_R21","doi-asserted-by":"crossref","unstructured":"Black A, Redmond AO, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother.1990;26:25\u201329","DOI":"10.1093\/jac\/26.suppl_F.25"},{"key":"2021120820240744900_R22","unstructured":"Kuhn R, Palmejar A, Kanga J. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis. Adv Antimicrob Antineopl Chemother.1992;11\u20132s:269\u2013271"},{"key":"2021120820240744900_R23","unstructured":"Dab I, Desmyttere S, Malfroot A. Repeated use of ciprofloxacin in a pediatric cystic fibrosis population. Adv Antimicrob Antineopl Chemother.1992;11\u20132s:143\u2013146"},{"key":"2021120820240744900_R24","unstructured":"Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, Menkes CJ. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis. Rev Rhum Mal Osteoartic.1989;56:735\u2013740"},{"key":"2021120820240744900_R25","doi-asserted-by":"crossref","unstructured":"Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J.2002;21:525\u2013529","DOI":"10.1097\/00006454-200206000-00009"},{"key":"2021120820240744900_R26","doi-asserted-by":"crossref","unstructured":"Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis.1990;13:153\u2013155","DOI":"10.1016\/0732-8893(90)90099-H"},{"key":"2021120820240744900_R27","unstructured":"Rahm V, Schacht P. Safety of ciprofloxacin. A review. Scand J Infect Dis Suppl.1989;60:120\u2013128"},{"key":"2021120820240744900_R28","doi-asserted-by":"crossref","unstructured":"Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection.1991;19:289\u2013296","DOI":"10.1007\/BF01644970"},{"key":"2021120820240744900_R29","unstructured":"Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J.1991;10:723\u2013729"},{"key":"2021120820240744900_R30","doi-asserted-by":"crossref","unstructured":"Cheesbrough JS, Mwema FI, Green SD, Tillotson GS. Quinolones in children with invasive salmonellosis. Lancet.1991;338:127 (letter)","DOI":"10.1016\/0140-6736(91)90127-B"},{"key":"2021120820240744900_R31","doi-asserted-by":"crossref","unstructured":"Singh UK, Sinha RK, Prasad B, Chakrabarti B, Sharma SK. Ciprofloxacin in children: is arthropathy a limitation?Indian J Pediatr.2000;67:386\u2013387","DOI":"10.1007\/BF02820695"},{"key":"2021120820240744900_R32","doi-asserted-by":"crossref","unstructured":"Pradhan KM, Arora NK, Jena A, Susheela AK, Bhan MK. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr.1995;84:555\u2013560","DOI":"10.1111\/j.1651-2227.1995.tb13694.x"},{"key":"2021120820240744900_R33","doi-asserted-by":"crossref","unstructured":"Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J.2000;19:1060\u20131067","DOI":"10.1097\/00006454-200011000-00006"},{"key":"2021120820240744900_R34","doi-asserted-by":"crossref","unstructured":"Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol.2000;34:87\u201391","DOI":"10.1002\/(SICI)1096-911X(200002)34:2<87::AID-MPO2>3.0.CO;2-F"},{"key":"2021120820240744900_R35","doi-asserted-by":"crossref","unstructured":"Doherty CP, Saha SK, Cutting WA. Typhoid fever, ciprofloxacin and growth in young children. Ann Trop Paediatr.2000;20:297\u2013303","DOI":"10.1080\/02724936.2000.11748151"},{"key":"2021120820240744900_R36","doi-asserted-by":"crossref","unstructured":"Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J.1997;16:572\u2013578","DOI":"10.1097\/00006454-199706000-00007"},{"key":"2021120820240744900_R37","doi-asserted-by":"crossref","unstructured":"Nelson JD, McCracken GH. The Pediatric Infectious Disease Journal Newsletter. Fluoroquinolones in pediatrics. Pediatr Infect Dis J.1998;17 Newsletter (yellow pages)","DOI":"10.1097\/00006454-199802000-00001"},{"key":"2021120820240744900_R38","doi-asserted-by":"crossref","unstructured":"Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis.1997;25:1196\u20131204","DOI":"10.1086\/516119"},{"key":"2021120820240744900_R39","doi-asserted-by":"crossref","unstructured":"Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients\u2014review. Infection.1993;21:413\u2013421","DOI":"10.1007\/BF01728929"},{"key":"2021120820240744900_R40","doi-asserted-by":"crossref","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981;30:239\u2013245","DOI":"10.1038\/clpt.1981.154"},{"key":"2021120820240744900_R41","doi-asserted-by":"crossref","unstructured":"Begaud B. Standardized assessment of adverse drug reactions: the method used in France. Special workshop\u2014clinical. Drug Inf J.1984;18:275\u2013281","DOI":"10.1177\/009286158401800314"},{"key":"2021120820240744900_R42","doi-asserted-by":"crossref","unstructured":"Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf.1995;13:343\u2013358","DOI":"10.2165\/00002018-199513060-00004"},{"key":"2021120820240744900_R43","unstructured":"Le Loet X, Fessard C, Noblet C, Ait Sait L, Moore N. Severe polyarthropathy in an adolescent treated with pefloxacin. J Rheumatol.1991;18:1941\u20131942"},{"key":"2021120820240744900_R44","unstructured":"Karande S, Kshirsagar NA. Ciprofloxacin use: acute arthropathy and long-term follow up. Indian Pediatr.1996;33:910\u2013916"},{"key":"2021120820240744900_R45","doi-asserted-by":"crossref","unstructured":"Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J.1997;16:118\u2013122; discussion 123\u2013126","DOI":"10.1097\/00006454-199701000-00034"},{"key":"2021120820240744900_R46","unstructured":"Wlazlowski J, Krzyzanska-Oberbek A, Sikora JP, Chlebna-Sokol D. Use of the quinolones in treatment of severe bacterial infections in premature infants. Acta Pol Pharm.2000;57:28\u201331"},{"key":"2021120820240744900_R47","doi-asserted-by":"crossref","unstructured":"Martell M, de Ben S, Weinberger M, Beltrami G. Growth and development in preterm infants receiving fluoroquinolones. J Perinat Med.1996;24:287\u2013291","DOI":"10.1515\/jpme.1996.24.3.287"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/6\/e714\/1010887\/pe060300e714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/6\/e714\/1010887\/pe060300e714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:20:37Z","timestamp":1639009237000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/111\/6\/e714\/28652\/Fluoroquinolone-Safety-in-Pediatric-Patients-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,1]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2003,6,1]]},"published-print":{"date-parts":[[2003,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.111.6.e714","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,1]]}}}